论文部分内容阅读
为了观察升白欣对癌症患者化疗、放疗所致的白细胞减少症的疗效，作者于１９９６年７月至８月，将化疗、放疗所致白细胞减少的６８例癌症患者，随机分成升白欣治疗组（３５例）和一般升白细胞药的对照组（３３例）。结果表明，升白欣的升白细胞有效率６０．０％，明显高于对照组的２１．２％（Ｐ＜０．０１），治疗前白细胞中位值为２．６７×１０９／Ｌ±０．７９×１０９／Ｌ，治疗后升高为４．２５×１０９／Ｌ±２．２９××１０９／Ｌ。升白欣的副反应主要为发热（３４．８％）、注射部位疼痛（６５．７％）。作者认为，升白欣治疗化疗、放疗后所致白细胞减少症是有效的，有临床应用价值。
In order to observe the effect of Shengbai Xin on leukopenia induced by chemotherapy and radiotherapy in cancer patients, the authors randomized 68 patients with leukopenia induced by chemotherapy and radiotherapy into Shengbai Xin treatment from July to August 1996 Group (35 cases) and general leukocyte drug control group (33 cases). The results showed that the Sheng Bai Xin effective leukocyte 60.0%, significantly higher than the control group 21.2% (P <0.01), before treatment, the median leukocyte 2.67 × 109 / L ± 0 .79 × 109 / L, increased to 4.25 × 109 / L ± 2.29 × 109 / L after treatment. Side Bai Xin side effects were mainly fever (34.8%), injection site pain (65.7%). The author believes that Sheng Bai Xin treatment of chemotherapy, leukopenia after radiotherapy is effective and has clinical value.